Dapagliflozin-Sitagliptin in T2D: Moving Beyond HbA1c Towards a Broader Orbit of Care Written By Dr. Sudhir Bhandari6 Nov 2026 11:00 AM ISTType 2 diabetes (T2D) is increasingly recognised as a complex gluco-cardio-metabolic disease requiring more than glycaemic control alone. India has...
Dapagliflozin Metformin in T2D: Six Potential Benefits Beyond Glucose Lowering-Dr Setu Gupta Written By Dr Setu Gupta1 July 2026 12:20 PM ISTWhile dapagliflozin-metformin dual fixed-dose combinations (FDCs) are increasingly used in type 2 diabetes (T2D) management, their complementary...
Dapagliflozin & Kidney: Top 5 New Evidence Highlights in 2026 Written By ATUL SAJGURE19 Jun 2026 10:30 AM ISTChronic kidney disease (CKD) is among the most common and serious complications of type 2 diabetes (T2D), affecting nearly 32% of Indian patients...
From Monotherapy to Multi-Drug Regimens: Metformin's Role as the Therapeutic Backbone for Over Seven Decades Written By Dr. RITESH KU. AGRAWALA12 Jun 2026 10:41 AM ISTFor over seven decades, metformin has remained the cornerstone of T2DM management as monotherapy and in combination with other glucose-lowering...
Dapagliflozin and Metformin in T2D: Three Important Indian Evidences Revisited- Dr Semanti Chakraborty Written By Dr. Semanti Chakraborty10 Jun 2026 11:09 AM ISTIndia's Type 2 diabetes(T2D) prevalence is increasing, with over half of affected individuals remaining undiagnosed. More than 70% of Indian T2D...
Orbit of Care in Indian T2D with CV Risk: Practice Update & Spotlight on Smart Application of Dapagliflozin & Sitagliptin FDC Written By Dr Manoj Chawla4 Jun 2026 10:56 AM ISTIn India, type 2 diabetes(T2D) clusters with cardiovascular risk and earlier age than in Western populations, mainly driven by visceral adiposity...
Dapagliflozin-Metformin in Obese T2D After GLP-RA: Assessing Newer Possibilities- Dr Bharat Saboo Written By Dr Bharat Saboo26 May 2026 10:37 AM ISTGlobally and in India, T2DM prevalence continues to rise, with obesity as one of its most important clinical drivers, reported in nearly 60-90% of...
Adding Metformin with GLP-1RA: What are the Five Points Clinicians Need to Know?- Dr NK Singh Written By Dr N K Singh14 May 2026 10:59 AM ISTIndia's metabolic burden is rising; T2DM prevalence, BMI, and cholesterol are all worsening. With the loss of injectable semaglutide exclusivity in...
Metformin: Anchor in the Metabolic Journey of Prediabetes Care- Dr Dwaipayan Deb Written By Dr Dwaipayan Deb29 April 2026 11:24 AM ISTPrediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% prevalence among Indian...
Metformin in Weight Loss Maintenance: A Possible Opportunity Post-GLP-RA Discontinuation?- Dr. Ashok Kumar Das Written By Dr. Ashok Kumar Das21 April 2026 12:14 PM ISTPatients who achieved weight loss with GLP-1 Receptor Agonists (RAs) can sustain their results with generic anti-obesity medications, including...
Dapagliflozin and Sitagliptin FDC in Indian T2D: 5 Points Clinicians May Like to Know - Dr K Baraneedharan Written By Dr. K. Baraneedharan9 April 2026 12:00 PM ISTThe burden of T2DM is increasing worldwide, with enormous implications for morbidity and mortality. Early and effective intervention is essential to...
Metformin: Anchoring Potential in GLP-1 RA Care Journey Written By Dr Manjunath Havalappa Dodamani8 April 2026 12:59 PM ISTIndia is confronting a metabolic health crisis of significant magnitude, 254 million adults with generalised obesity, 351 million with abdominal...
